rs1554334905
Variant summary
Our verdict is Uncertain significance. The variant received 5 ACMG points: 6P and 1B. PM5_SupportingPM1PP2PP3PM2_SupportingBP2
This summary comes from the ClinGen Evidence Repository: The c.883G>C variant in the glucokinase gene, GCK, causes an amino acid change of glycine to arginine at codon 295 (p.(Gly295Arg)) of NM_000162.5. This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.99, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and this variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant resides in an amino acid that directly binds ATP, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies). In this individual the variant was in cis with the variant c.1361C>A p.Ala454Gly, which has been classified as likely pathogenic by the ClinGen MDEP, and thus PP4_Moderate was not applied (BP2). Three other missense variants, c.883G>A p.Gly295Ser, c.884G>A p.Gly295Asp, and c.884G>T p.Gly295Val, have been classified as likely pathogenic by the ClinGen MDEP (PM5_Supporting). In summary, c.883G>C meets the criteria to be classified as a variant of uncertain significance for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM1, BP2, PP2, PP3, PM2_Supporting, PM5_Supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA367400138/MONDO:0015967/086
Frequency
Consequence
NM_000162.5 missense
Scores
Clinical Significance
Conservation
Publications
- hyperinsulinism due to glucokinase deficiencyInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics, Orphanet
- maturity-onset diabetes of the young type 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, Ambry Genetics
- monogenic diabetesInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen
- diabetes mellitus, noninsulin-dependentInheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp
- permanent neonatal diabetes mellitus 1Inheritance: AR Classification: STRONG, MODERATE Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae), Ambry Genetics
- transient neonatal diabetes mellitusInheritance: AR Classification: STRONG Submitted by: Genomics England PanelApp
- maturity-onset diabetes of the youngInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- permanent neonatal diabetes mellitusInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 5 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GCK | NM_000162.5 | c.883G>C | p.Gly295Arg | missense_variant | Exon 8 of 10 | ENST00000403799.8 | NP_000153.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| GCK | ENST00000403799.8 | c.883G>C | p.Gly295Arg | missense_variant | Exon 8 of 10 | 1 | NM_000162.5 | ENSP00000384247.3 |
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD2 exomes AF: 0.00 AC: 0AN: 249622 AF XY: 0.00
GnomAD4 exome Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Monogenic diabetes Uncertain:1
The c.883G>C variant in the glucokinase gene, GCK, causes an amino acid change of glycine to arginine at codon 295 (p.(Gly295Arg)) of NM_000162.5. This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.99, which is greater than the MDEP VCEP threshold of 0.70 (PP3) and this variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant resides in an amino acid that directly binds ATP, which is defined as critical for the protein’s function by the ClinGen MDEP (PM1). This variant was identified in an individual with a clinical history highly specific for GCK-hyperglycemia (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and negative antibodies). In this individual the variant was in cis with the variant c.1361C>A p.Ala454Gly, which has been classified as likely pathogenic by the ClinGen MDEP, and thus PP4_Moderate was not applied (BP2). Three other missense variants, c.883G>A p.Gly295Ser, c.884G>A p.Gly295Asp, and c.884G>T p.Gly295Val, have been classified as likely pathogenic by the ClinGen MDEP (PM5_Supporting). In summary, c.883G>C meets the criteria to be classified as a variant of uncertain significance for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.3.0, approved 8/11/2023): PM1, BP2, PP2, PP3, PM2_Supporting, PM5_Supporting. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at